BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38578670)

  • 1. Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists.
    Sheng D; Yue CX; Jin F; Wang Y; Ichikawa M; Yu Y; Guo CR; Hattori M
    Elife; 2024 Apr; 12():. PubMed ID: 38578670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Structural Biology Has Directly Impacted Our Understanding of P2X Receptor Function and Gating.
    Mansoor SE
    Methods Mol Biol; 2022; 2510():1-29. PubMed ID: 35776317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region.
    Huo H; Fryatt AG; Farmer LK; Schmid R; Evans RJ
    J Biol Chem; 2018 Aug; 293(33):12820-12831. PubMed ID: 29997254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actions of a Series of PPADS Analogs at P2X
    Brown SG; Kim YC; Kim SA; Jacobson KA; Burnstock G; King BF
    Drug Dev Res; 2001 Aug; 53(4):281-291. PubMed ID: 27134334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.
    Farmer LK; Schmid R; Evans RJ
    J Biol Chem; 2015 Jan; 290(3):1559-69. PubMed ID: 25425641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels.
    Nicke A; Bäumert HG; Rettinger J; Eichele A; Lambrecht G; Mutschler E; Schmalzing G
    EMBO J; 1998 Jun; 17(11):3016-28. PubMed ID: 9606184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cultured dorsal root ganglion neuron P2X receptors.
    Grubb BD; Evans RJ
    Eur J Neurosci; 1999 Jan; 11(1):149-54. PubMed ID: 9987019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel.
    Kasuya G; Yamaura T; Ma XB; Nakamura R; Takemoto M; Nagumo H; Tanaka E; Dohmae N; Nakane T; Yu Y; Ishitani R; Matsuzaki O; Hattori M; Nureki O
    Nat Commun; 2017 Oct; 8(1):876. PubMed ID: 29026074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergent effects of the purinoceptor antagonists suramin and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
    Suzuki E; Kessler M; Montgomery K; Arai AC
    Mol Pharmacol; 2004 Dec; 66(6):1738-47. PubMed ID: 15448189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mechanism of inhibition by the P2 receptor antagonist PPADS of ATP-activated current in dorsal root ganglion neurons.
    Li C
    J Neurophysiol; 2000 May; 83(5):2533-41. PubMed ID: 10805655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Molecular Determinants of Small-Molecule Ligand Binding at P2X Receptors.
    Pasqualetto G; Brancale A; Young MT
    Front Pharmacol; 2018; 9():58. PubMed ID: 29456508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2X purinergic receptor knockout mice reveal endogenous ATP modulation of both vasopressin and oxytocin release from the intact neurohypophysis.
    Custer EE; Knott TK; Cuadra AE; Ortiz-Miranda S; Lemos JR
    J Neuroendocrinol; 2012 Apr; 24(4):674-80. PubMed ID: 22340257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP modulates noradrenaline release by activation of inhibitory P2Y receptors and facilitatory P2X receptors in the rat vas deferens.
    Queiroz G; Talaia C; Gonçalves J
    J Pharmacol Exp Ther; 2003 Nov; 307(2):809-15. PubMed ID: 12966150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics.
    Honore P; Mikusa J; Bianchi B; McDonald H; Cartmell J; Faltynek C; Jarvis MF
    Pain; 2002 Mar; 96(1-2):99-105. PubMed ID: 11932066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
    Kim YC; Brown SG; Harden TK; Boyer JL; Dubyak G; King BF; Burnstock G; Jacobson KA
    J Med Chem; 2001 Feb; 44(3):340-9. PubMed ID: 11462975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice.
    Tsuda M; Ueno S; Inoue K
    Br J Pharmacol; 1999 Dec; 128(7):1497-504. PubMed ID: 10602329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
    Jacobson KA; Kim YC; Wildman SS; Mohanram A; Harden TK; Boyer JL; King BF; Burnstock G
    J Med Chem; 1998 Jun; 41(13):2201-6. PubMed ID: 9632352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purinergic P2X receptors: structural models and analysis of ligand-target interaction.
    Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R
    Eur J Med Chem; 2015 Jan; 89():561-80. PubMed ID: 25462266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
    Evans RJ; Lewis C; Buell G; Valera S; North RA; Surprenant A
    Mol Pharmacol; 1995 Aug; 48(2):178-83. PubMed ID: 7544432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of run-down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels.
    Lewis CJ; Evans RJ
    Br J Pharmacol; 2000 Dec; 131(8):1659-66. PubMed ID: 11139444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.